The ABCC4 gene is a promising target for pancreatic cancer therapy

Gene

Volumn 491, Issue 2, 2012, Pages 194-199

  Zhang, Zhuo ^a   Wang, Jiancheng ^a   Shen, Baiyong ^a   Peng, Chenghong ^a   Zheng, Minhua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ABCC4; Gene therapy; Pancreatic cancer

Indexed keywords

ABC TRANSPORTER; ABCC4 PROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE TARGETING; GENE THERAPY; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING;

LENTIVIRUS;

EID: 81455158692     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.09.029     Document Type: Article

References (20)

1. Borst P., Elferink R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002, 71:537-592.
2. Borst P., de Wolf C., van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007, 453:661-673.
3. Brummelkamp T.R., Bernards R., Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2:243-247.
4. Crnkovic-Mertens I., Hoppe-Seyler F., Butz K. Induction of apoptosis in tumor by siRNA-medicated silencing of the livin/ML-IAP/KIAP gene. Oncogene 2003, 22:8330-8336.
5. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
6. Deeley R.G., Westlake C., Cole S.P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 2006, 86:849-899.
7. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 2010, 10:147-156.
8. Ghaneh P., Costello E., Neoptolemos J.P. Biology and management of pancreatic cancer. Gut 2007, 56:1134-1152.
9. Ho L.L., Kench J.G., Handelsman D.J., Scheffer G.L., Stricker P.D., Grygiel J.G. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate 2008, 68:1421-1429.
10. Hosono T., et al. RNA interference of PPARgamma using fiber-modified adenovirus vector efficiently suppresses preadipocyte-to-adipocyte differentiation in 3T3-L1 cells. Gene 2005, 348:157-165.
11. Konig J., et al. Expression and localization of human multidrug resistance (ABCC) family members in pancreatic carcinoma. Int. J. Cancer 2005, 115:359-367.
12. Kool M., et al. Analysis of expression of cMOAT(MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997, 57:3537-3547.
13. Luo Q., et al. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing. Gene 2007, 395:160-169.
14. Martinez L.A., et al. Synthetic small inhibiting RNAs; efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14849-14854.
15. Norris M.D., et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol. Cancer Ther. 2005, 4:547-553.
16. Rubinson D.A., et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 2003, 33:401-406.
17. Sauna Z.E., Nandigama K., Ambudkar S.V. Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state. J. Biol. Chem. 2004, 279:48855-48864.
18. Schuetz J.D., et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 1999, 5:1048-1051.
19. Sinn P.L., Sauter S.L., McCray P.B. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther. 2005, 12:1089-1098.
20. Steinbach D., et al. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse outcome in male patients and T-cell immunophenotype. Blood 2003, 102:4493-4498.